Abstract：
OBJECTIVE: Lung cancer, primarily non-small cell lung cancer (NSCLC), is the leading cause of cancer deaths globally. In Greece in 2020, 8,960 new cases were reported. NSCLC\'s 5-year survival rates range from 54% (stage I) to less than 2% (stage IV); however, innovative therapies like immune check points inhibitors (ICIs) and targeted treatments have notably enhanced outcomes. The aim of this study was to assess the 1st and 2nd line treatment patterns with the introduction of new treatment modalities. Additionally, we evaluated biomarker testing approaches in NSCLC.
METHODS: LACHESIS was a retrospective multinational study, collecting and analyzing data from adult patients from Russia, Bulgaria, and Greece with metastatic NSCLC either newly diagnosed or relapsed from earlier stages, who had the option to undergo biomarker testing (genetic alterations/programmed death-ligand 1 protein expression levels, PD-L1), and who received 1st line treatment for squamous (SQ) or non-squamous (N-SQ) NSCLC. Subsequent lines of therapy were also reported.
RESULTS: The Greek site registered retrospective data from 250 NSCLC patients, of whom 206 were newly diagnosed (ND) metastatic NSCLC patients and 44 were patients relapsed from earlier stages. Seventy-two had SQ NSCLC and 169 had N-SQ NSCLC. For these patients, treatment patterns including immunotherapy±chemotherapy combinations were recorded. Biomarker testing patterns, including genetic alterations and PD-L1 expression levels were also documented.
CONCLUSIONS: LACHESIS provides treatment patterns and biomarker testing data. Greek patients were treated according to international guidelines, with immunotherapy as a viable option, particularly for PD-L1 levels over 50%. Biomarker testing, crucial for non-squamous (N-SQ) cases, should yield timely results for driver mutations, prioritizing patient benefits.
METHODS: LACHESIS was a retrospective multinational study, collecting and analyzing data from adult patients from Russia, Bulgaria, and Greece with metastatic NSCLC either newly diagnosed or relapsed from earlier stages, who had the option to undergo biomarker testing (genetic alterations/programmed death-ligand 1 protein expression levels, PD-L1), and who received 1st line treatment for squamous (SQ) or non-squamous (N-SQ) NSCLC. Subsequent lines of therapy were also reported.
RESULTS: The Greek site registered retrospective data from 250 NSCLC patients, of whom 206 were newly diagnosed (ND) metastatic NSCLC patients and 44 were patients relapsed from earlier stages. Seventy-two had SQ NSCLC and 169 had N-SQ NSCLC. For these patients, treatment patterns including immunotherapy±chemotherapy combinations were recorded. Biomarker testing patterns, including genetic alterations and PD-L1 expression levels were also documented.
CONCLUSIONS: LACHESIS provides treatment patterns and biomarker testing data. Greek patients were treated according to international guidelines, with immunotherapy as a viable option, particularly for PD-L1 levels over 50%. Biomarker testing, crucial for non-squamous (N-SQ) cases, should yield timely results for driver mutations, prioritizing patient benefits.
摘要：
目标：肺癌，主要为非小细胞肺癌（NSCLC），是全球癌症死亡的主要原因。2020年，希腊报告了8,960例新病例。NSCLC的5年生存率范围从54%（I期）到小于2%（IV期）；然而，免疫检查点抑制剂(ICIs)和靶向治疗等创新疗法显著改善了预后.这项研究的目的是通过引入新的治疗方式来评估一线和二线治疗模式。此外,我们评估了非小细胞肺癌的生物标志物检测方法.
方法：LACHESIS是一项回顾性跨国研究，收集和分析来自俄罗斯的成年患者的数据，保加利亚,希腊转移性非小细胞肺癌新诊断或早期复发，谁可以选择进行生物标志物测试（遗传改变/程序性死亡配体1蛋白表达水平，PD-L1),以及接受鳞状细胞肺癌（SQ）或非鳞状细胞肺癌（N-SQ）一线治疗的患者。还报道了随后的治疗路线。
结果：希腊网站注册了250例NSCLC患者的回顾性数据，其中206例为新诊断（ND）转移性NSCLC患者，44例为早期复发患者。72例SQNSCLC和169例N-SQNSCLC。对于这些患者来说,记录了包括免疫治疗±化疗组合在内的治疗模式.生物标志物测试模式，还记录了基因改变和PD-L1表达水平。
结论：LACHESIS提供治疗模式和生物标志物测试数据。希腊患者根据国际准则接受治疗，将免疫疗法作为可行的选择，特别是PD-L1水平超过50%。生物标志物测试,对于非鳞状(N-SQ)病例至关重要，应该对驱动突变产生及时的结果，优先考虑患者的利益。
方法：LACHESIS是一项回顾性跨国研究，收集和分析来自俄罗斯的成年患者的数据，保加利亚,希腊转移性非小细胞肺癌新诊断或早期复发，谁可以选择进行生物标志物测试（遗传改变/程序性死亡配体1蛋白表达水平，PD-L1),以及接受鳞状细胞肺癌（SQ）或非鳞状细胞肺癌（N-SQ）一线治疗的患者。还报道了随后的治疗路线。
结果：希腊网站注册了250例NSCLC患者的回顾性数据，其中206例为新诊断（ND）转移性NSCLC患者，44例为早期复发患者。72例SQNSCLC和169例N-SQNSCLC。对于这些患者来说,记录了包括免疫治疗±化疗组合在内的治疗模式.生物标志物测试模式，还记录了基因改变和PD-L1表达水平。
结论：LACHESIS提供治疗模式和生物标志物测试数据。希腊患者根据国际准则接受治疗，将免疫疗法作为可行的选择，特别是PD-L1水平超过50%。生物标志物测试,对于非鳞状(N-SQ)病例至关重要，应该对驱动突变产生及时的结果，优先考虑患者的利益。
